- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Abbvie Inc DRC (ABBVm)Abbvie Inc DRC stock price live, this page displays BCBA ABBVm stock exchange data. View the ABBVm premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Abbvie Inc DRC real time stock price chart below.
What Is the Abbvie Inc DRC Stock Price Today?
The Abbvie Inc DRC stock price today is 18,700.00.
What Is the Stock Symbol for Abbvie Inc DRC?
The stock symbol for Abbvie Inc DRC is "ABBVm."
What Stock Exchange Does Abbvie Inc DRC Trade On?
Abbvie Inc DRC is listed and trades on the Buenos Aires stock exchange.
Is Abbvie Inc DRC a Good Stock to Buy?
Determining whether Abbvie Inc DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABBVm quote. (ISIN: ARBCOM4603M9)
What Is the Abbvie Inc DRC Stock Price Today?
The Abbvie Inc DRC stock price today is 18,700.00.
What Is the Stock Symbol for Abbvie Inc DRC?
The stock symbol for Abbvie Inc DRC is "ABBVm."
What Stock Exchange Does Abbvie Inc DRC Trade On?
Abbvie Inc DRC is listed and trades on the Buenos Aires stock exchange.
Is Abbvie Inc DRC a Good Stock to Buy?
Determining whether Abbvie Inc DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABBVm quote. (ISIN: ARBCOM4603M9)
18,700.00
-225.00(-1.19%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18,625.00
19,025.00
52 wk Range
13,286.66
26,225.00
ABBVm Scorecard
Full Analysis
Has raised its dividend for 12 consecutive years
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18,625.0019,025.00
52 wk Range
13,286.6626,225.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.52%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.52%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
ABBVm Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- This pharma stock is TD Cowen's Best Idea for 2025
- Investing.com
Pro
- This pharma stock is TD Cowen's Best Idea for 2025
- Investing.com
Pro - AbbVie Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - AbbVie Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Abbvie Company Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Compare ABBVm to Peers and Sector
Metrics to compare | ABBVm | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABBVmPeersSector | |
|---|---|---|---|---|
P/E Ratio | 61.4x | −1.7x | −0.7x | |
PEG Ratio | −2.86 | 0.03 | 0.00 | |
Price/Book | 51.7x | 5.1x | 2.6x | |
Price / LTM Sales | 5.6x | 10.0x | 3.2x | |
Upside (Analyst Target) | - | 441.0% | 47.1% | |
Fair Value Upside | Unlock | 15.2% | 7.3% | Unlock |
Dividends
Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.87
Dividend Yield
3.53%
Industry Median 1.10%
Annualised payout
667.1616
Paid quarterly
5-Years Growth
-
Growth Streak
FAQ
What Is the Abbvie (ABBVm) Stock Price Today?
The Abbvie stock price today is 18,700.00.
What Stock Exchange Does Abbvie Trade On?
Abbvie is listed and trades on the Buenos Aires stock exchange.
What Is the Stock Symbol for Abbvie?
The stock symbol for Abbvie is "ABBVm."
Does Abbvie Pay Dividends? What’s The Current Dividend Yield?
The Abbvie dividend yield is 3.52%.
What Is the Abbvie Market Cap?
As of today, Abbvie market cap is 314.92T.
What is Abbvie Earnings Per Share?
The Abbvie EPS is 2.87.
From a Technical Analysis Perspective, Is ABBVm a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.